These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.LYSODREN® (mitotane) tablets, for oral useInitial U.S. Approval: 1970

These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.LYSODREN® (mitotane) tablets, for oral useInitial U.S. Approval: 1970

Drug Labeling and Warnings

Drug Details

k">

LYSODREN- mitotane tablet 
E.R. Squibb & Sons, L.L.C.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN.
LYSODREN® (mitotane) tablets, for oral use
Initial U.S. Approval: 1970

WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

See full prescribing information for complete boxed warning.

In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery. (2.25.1)

RECENT MAJOR CHANGES

Ovarian Macrocysts in Premenopausal Women (5.5)                                    5/2017

INDICATIONS AND USAGE

LYSODREN is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma. (1)

DOSAGE AND ADMINISTRATION

Initial dose: 2 g to 6 g orally daily, in three or four divided doses. (2.1)

Increase dose incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. (2.1)

DOSAGE FORMS AND STRENGTHS

Tablets: 500 mg, scored (3)

CONTRAINDICATIONS

None (4)

WARNINGS AND PRECAUTIONS

Central Nervous System (CNS) Toxicity: Plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity. (5.2)

Adrenal Insufficiency: Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement. (5.3)

Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of reproductive potential of the potential risk to a fetus and use of effective contraception. (5.4, 8.1, 8.3)

Ovarian Macrocysts in Premenopausal Women: Advise women to seek medical advice if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain. (5.5)

ADVERSE REACTIONS

Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Adjust dosage of concomitant coumarin-type anticoagulants as needed. (7.2)

USE IN SPECIFIC POPULATIONS

  • Lactation: Do not breastfeed. (8.2)
  • Hepatic Impairment: Administer LYSODREN with caution to patients with hepatic impairment. (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 7/2018

FULL PRESCRIBING INFORMATION

WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR SEVERE TRAUMA

In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue LYSODREN until recovery [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dose

The recommended initial dose of LYSODREN is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated.

LYSODREN is a cytotoxic drug. Follow applicable special handling and disposal procedures.

2.2 Dose Modifications

Adrenal Crisis in the Setting of Shock or Severe Trauma

Discontinue LYSODREN until recovery [see Warnings and Precautions (5.1)].

Central Nervous System (CNS) Toxicity

Discontinue LYSODREN until symptoms resolve. Seven to 10 days after symptoms resolve, restart at a lower dose (for example, decrease by 500-1000 mg) [see Warnings and Precautions (5.2)].

3 DOSAGE FORMS AND STRENGTHS

500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with “BL” over “L1” on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Adrenal Crisis in the Setting of Shock or Severe Trauma

In patients taking LYSODREN, adrenal crisis occurs in the setting of shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock, and discontinue LYSODREN until recovery [see Dosage and Administration (2.2)].

5.2 CNS Toxicity

CNS toxicity, including sedation, lethargy, and vertigo, occurs with LYSODREN treatment. Mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of toxicity.

5.3 Adrenal Insufficiency

Treatment with LYSODREN can cause adrenal insufficiency. Institute steroid replacement as clinically indicated. Measure free cortisol and corticotropin (ACTH) levels to achieve optimal steroid replacement.

5.4 Embryo-Fetal Toxicity

LYSODREN can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes, such as preterm births and early pregnancy loss, can occur in patients exposed to mitotane during pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LYSODREN and after discontinuation of treatment for as long as mitotane plasma levels are detectable [see Use in Specific Populations (8.18.3)].

5.5 Ovarian Macrocysts in Premenopausal Women

Ovarian macrocysts, often bilateral and multiple, have been reported in premenopausal patients receiving LYSODREN. Complications from these cysts, including adnexal torsion and hemorrhagic cyst rupture, have been reported. In some cases, improvement after mitotane discontinuation has been described. Advise female patients to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [seeAdverse Reactions (6)].

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

  Adrenal Crisis in the Setting of Shock or Severe Trauma [see Warnings and Precautions (5.1)]

   CNS Toxicity [seeWarnings and Precautions (5.2)]

   Adrenal Insufficiency [seeWarnings and Precautions (5.3)]
   Ovarian macrocysts [seeWarnings and Precautions (5.5)]

The following adverse reactions associated with the use of LYSODREN were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

Common adverse reactions occurring with LYSODREN treatment include:

Anorexia, nausea, vomiting, and diarrhea (80%)

Depression, dizziness, or vertigo (15%-40%)

Rash (15%)NeutropeniaGrowth retardation, hypothyroidism

Confusion, headache, ataxia, mental impairment, weakness, dysarthria

MaculopathyHepatitis, elevation of liver enzymesGynecomastia

   Hypercholesterolemia, hypertriglyceridemia

Decreased blood androstenedione and decreased blood testosterone in females, increased sex hormone binding globulin in females      and males, decreased blood free testosterone in males.

Less common adverse reactions include: visual blurring, diplopia, lens opacity, retinopathy, prolonged bleeding time, hematuria, hemorrhagic cystitis, albuminuria, hypertension, orthostatic hypotension, flushing, generalized aching, and fever.

7 DRUG INTERACTIONS

7.1 CYP3A4 Substrates

Mitotane is a strong inducer of cytochrome P450 3A4 (CYP3A4). Monitor patients for a change in dosage requirements for the concomitant drug when administering LYSODREN to patients receiving drugs that are substrates of CYP3A4.

7.2 Warfarin

When administering coumarin-type anticoagulants to patients receiving LYSODREN, monitor coagulation tests and adjust the anticoagulant dose as needed.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

LYSODREN can cause fetal harm. Limited postmarketing cases report preterm births and early pregnancy loss in women treated with LYSODREN during pregnancy. Animal reproduction studies have not been conducted with mitotane. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

Risk Summary

Mitotane is excreted in human milk; however, the effect of LYSODREN on the breastfed infant, or effect on milk production is unknown. Because of the potential for serious adverse reactions in the breastfed infant, advise nursing women that breastfeeding is not recommended during treatment with LYSODREN and after discontinuation of treatment for as long as mitotane plasma levels are detectable.

8.3 Females and Males of Reproductive Potential

Contraception

Females

LYSODREN can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]Advise female patients of reproductive potential to use effective contraception during treatment with LYSODREN and after discontinuation of therapy for as long as mitotane plasma levels are detectable [see Clinical Pharmacology (12.3)].

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies of LYSODREN did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8.6 Hepatic Impairment

Hepatic impairment may interfere with the metabolism of mitotane and the drug may accumulate. Administer LYSODREN with caution to patients with hepatic impairment.

11 DESCRIPTION

LYSODREN (mitotane) is an oral adrenal cytotoxic agent. The chemical name is (±)-1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane (also known as o,p′-DDD). The chemical structure is:

Image Mitotane Chemical Structure

Mitotane is a white granular solid composed of clear colorless crystals. It is tasteless and has a slight pleasant aromatic odor. It is soluble in ethanol and has a molecular weight of 320.05.

Inactive ingredients in LYSODREN are: microcrystalline cellulose, polyethylene glycol 3350, silicon dioxide, and starch.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid concentrations and increased formation of 6-β-hydroxycortisol have been reported.

12.2 Pharmacodynamics

The pharmacodynamics of mitotane are unknown.

12.3 Pharmacokinetics

Absorption

Following oral administration of LYSODREN, 40% of the dose is absorbed.

Distribution

Mitotane is found in most tissues of the body; however, fat is the primary site of distribution.

Elimination

Following discontinuation of mitotane, the plasma terminal half-life ranges from 18 to 159 days (median 53 days).

Metabolism

Mitotane is converted to a water-soluble metabolite.

Excretion

No unchanged mitotane is found in urine or bile. Approximately 10% of the administered dose is recovered in the urine as a water-soluble metabolite. A variable amount of metabolite (1%-17%) is excreted in the bile.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

The carcinogenicity and mutagenicity of mitotane are unknown.

16 HOW SUPPLIED/STORAGE AND HANDLING

LYSODREN tablets are supplied as 500 mg white, round, biconvex, scored tablets, bisected on one side and impressed with “BL” over “L1” on the other side.

100 tablets per bottle: NDC: 0015-3080-60

Store bottles at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F-86°F).

Mitotane is a cytotoxic drug. Follow applicable special handling and disposal procedures [see References (15)].

17 PATIENT COUNSELING INFORMATION

Adrenal Crisis

  • Advise patients to discontinue LYSODREN in the case of shock or severe trauma and contact their healthcare provider immediately.
  • Advise patients to tell their healthcare provider of any planned surgeries.

Ovarian Macrocysts

Advise premenopausal women to seek medical care if they experience gynecological symptoms such as vaginal bleeding and/or pelvic pain [see Warnings and Precautions(5.5)].

Embryo-Fetal Toxicity

Lactation

Manufactured for:
Bristol-Myers Squibb Company
Princeton, New Jersey 08543 USA


TBD

LYSODREN 500 mg Tablets Representative Packaging

See How Supplied section for a complete list of available packages of LYSODREN.

NDC: 0015-3080-60
100 TABLETS
LYSODREN® (mitotane tablets, USP)
EACH TABLET CONTAINS 500 mg
Rx only
Bristol-Myers Squibb

Image Lysodren 500 mg Tablets Label
LYSODREN 
mitotane tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0015-3080
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
mitotane (UNII: 78E4J5IB5J) (mitotane - UNII:78E4J5IB5J) mitotane500 mg
Inactive Ingredients
Ingredient NameStrength
cellulose, microcrystalline (UNII: OP1R32D61U)  
polyethylene glycol 3350 (UNII: G2M7P15E5P)  
silicon dioxide (UNII: ETJ7Z6XBU4)  
Product Characteristics
ColorwhiteScore2 pieces
ShapeROUNDSize13mm
FlavorImprint Code BL;L1
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 0015-3080-60100 in 1 BOTTLE; Type 0: Not a Combination Product06/01/200903/31/2021
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01688506/01/200903/31/2021
Labeler - E.R. Squibb & Sons, L.L.C. (968242821)

Revised: 7/2018
 
E.R. Squibb & Sons, L.L.C.


© 2019 FDA.report
This site is not affiliated with or endorsed by the FDA.